PLN-101325 / Pliant Therapeutics - LARVOL DELTA

PLN-101325 for treatment of muscular dystrophies (GlobeNewswire) - "PLN-101325 is a monoclonal antibody that acts as an allosteric agonist of integrin α7β1, currently in development for treatment of muscular dystrophies. PLN-101325 is Phase 1 ready with clinical trial approval (CTA) open in Australia."

New P1 trial • Muscular Dystrophy

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire) - "Phase 1 trial of PLN-101095 in solid tumors is progressing with dosing of the third of five cohorts...The Company is currently enrolling the third of five cohorts in the Phase 1 open label, dose-escalation trial of PLN-101095 as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. Preliminary data is expected in late 2024 or early 2025....Based on preclinical data, PLN-101325 may have the potential to treat additional indications in organ systems outside of muscle. The Company is currently generating additional evidence in support of potential expansion of the scope of PLN-101325 prior to initiating a Phase 1 trial."

P1 data • Preclinical • Trial status • Genetic Disorders • Muscular Dystrophy • Oncology • Solid Tumor

Activation of Muscle α7-Integrin Restores Sarcolemma Integrity and Improves Dystrophic Pathology (MDA 2024) - "These results demonstrate that PLN-101325 improves the DMD phenotype by strengthening the link between muscle cell cytoskeleton and the ECM to improve sarcolemma membrane integrity and restore intracellular ionic balance, leading to enhanced resistance to muscle injury. Altogether, these data demonstrate agonists to human α7-integrin represent an effective strategy to ameliorate the myopathic phenotype of DMD."

Duchenne Muscular Dystrophy • Fibrosis • Genetic Disorders • Immunology • Inflammation • Muscular Dystrophy • Myositis

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) - "Initiation of BEACON-IPF, a Phase 2b trial of bexotegrast in patients with IPF, expected in mid-2023. BEACON-IPF is a 52-week, multinational, randomized, placebo-controlled trial evaluating bexotegrast at doses of 160 mg or 320 mg in approximately 270 patients with IPF; INTEGRIS-PSC Phase 2a 12-week clinical data expected in the third quarter of 2023...approximately 84 patients with primary sclerosing cholangitis (PSC); Initiation of a Phase 1 first-in-human trial of PLN-101095 in oncology expected in the second quarter of 2023...Initiation of a Phase 1 trial in patients with solid tumors that are resistant to immune checkpoint inhibitors is expected in the second quarter of 2023; Muscular dystrophy program progressing through IND enabling activities. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of the integrin α7β1. An IND submission for Duchenne muscular dystrophy (DMD) is expected in 2023."

IND • New P1 trial • New P2b trial • P2a data • Duchenne Muscular Dystrophy • Idiopathic Pulmonary Fibrosis • Muscular Dystrophy • Oncology • Respiratory Diseases • Solid Tumor